Academic Journals Database
Disseminating quality controlled scientific knowledge

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor 
Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer

Author(s): Yuan LI | Lihua SONG

Journal: Chinese Journal of Lung Cancer
ISSN 1009-3419

Volume: 15;
Issue: 2;
Start page: 106;
Date: 2012;
Original page

Keywords: Epidermal growth factor receptor-tyrosine kinase inhibitors | Lung neoplasms | Drug resistance | Mechanism

With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. However, the efficacy of EGFR-TKIs is limited by either primary (de novo) or acquired resistance after therapy. This review will focus on recently identified mechanisms of primary and acquired resistance to EGFR TKIs and strategies currently being employed to overcome resistance.
Save time & money - Smart Internet Solutions     

Tango Rapperswil
Tango Rapperswil